Nexalis Therapeutics (ASX:NX1) — Material Events
ASX:NX1 · 10 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Nexalis Screens First Patient in Phase 2 Trial Targeting Breakthrough Cancer PainMedium
Nexalis screens first patient in Phase 2 trial of IRX-211 for breakthrough cancer pain
20 Apr 2026
·Clinical Trial Update
·80
Nexalis Launches First Human Trial of Inhaled CBD for Panic DisorderMedium
Nexalis Therapeutics begins Phase 1 trial of inhaled CBD therapy IRX-616a for Panic Disorder
4 Mar 2026
·Clinical Trial Commencement Announcement
·80
Nexalis Therapeutics Faces Funding Setback as Losses Deepen and Trials PauseMedium
Nexalis Therapeutics reports increased loss, funding facility cancellation, and clinical trial suspension
1 Sept 2026
·Interim Financial Report
·Unexpected
·75
Nexalis Therapeutics Advances with $150k Placement and New Options IssuedMedium
Nexalis Therapeutics completes security allotment post shareholder approval, advancing clinical-stage drug development
17 Feb 2026
·Allotment of Securities
·70
Nexalis Therapeutics Launches First Human Trial of IRX-616a for Panic DisorderMedium
Nexalis Therapeutics Begins Phase 1 Trial of IRX-616a for Panic Disorder
19 Mar 2026
·Clinical Trial Commencement Announcement
·70
Nexalis Therapeutics Halts Point8 Funding Talks, Completes IRX-616a Phase 1 Trial with Positive ResultsMedium
Nexalis Therapeutics halts Point8 funding talks, completes IRX-616a Phase 1 trial with positive results, reassesses clinical plans
6 July 2026
·Corporate Update
·Unexpected
·65
Nexalis Therapeutics Posts $1.83M Loss Amid Rising Development CostsMedium
Nexalis Therapeutics reports $1.83M loss for 2025 with increased cash and equity raises
27 Feb 2026
·Preliminary Final Report
·60
Nexalis Therapeutics Links Director Fees to Phase 2 Trial Milestones with Share RightsMedium
Nexalis Therapeutics issues share rights to directors in lieu of fees with vesting tied to Phase 2 trial success
14 July 2026
·Director Remuneration Announcement
·50
Nexalis Therapeutics Suspends Trading Ahead of Debt Facility UpdateMedium
Nexalis Therapeutics Requests Voluntary Suspension Pending Debt Facility Announcement
26 May 2026
·Voluntary Suspension Request
·50
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Nexalis Therapeutics (ASX:NX1) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 28 (6 July -> 10 July) 2026
11 July 2026
Healthcare Wrap - Week 22 (25 May -> 29 May) 2026
30 May 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026